仟源医药(300254) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥223,082,273.77, representing a 47.70% increase compared to ¥151,034,346.90 in the same period last year[7]. - Net profit attributable to shareholders was ¥1,018,515.83, a significant turnaround from a loss of ¥43,650,138.12, marking a 102.33% improvement[7]. - Basic earnings per share improved to ¥0.0045 from a loss of ¥0.2095, indicating a 102.15% increase[7]. - The company's revenue for the reporting period was 223.08 million, an increase of 47.70% compared to the same period last year, primarily due to the recovery of pharmaceutical sales following the control of the COVID-19 pandemic and increased sales of new products such as Sincalide and Rivaroxaban tablets[20]. - The company's net loss for the period was CNY 51,847,163.56, an improvement from a loss of CNY 77,037,479.23 in the previous year[42]. - The total profit for the first quarter was CNY 5,506,915.76, a significant improvement from a loss of CNY 45,869,462.36 in the prior year[46]. Cash Flow - The net cash flow from operating activities reached ¥15,554,487.31, compared to a negative cash flow of ¥17,385,577.38 in the previous year, reflecting a 189.47% increase[7]. - The company's cash flow from operating activities was 15.55 million, an increase of 189.47% year-on-year, primarily due to increased cash received from sales of goods and government subsidies[19]. - The net cash flow from operating activities for Q1 2021 was ¥15,554,487.31, a significant improvement compared to a net outflow of ¥17,385,577.38 in Q1 2020[54]. - Total cash inflow from investment activities was ¥1,400.00, while cash outflow was ¥9,221,527.50, resulting in a net cash flow of -¥9,220,127.50 for Q1 2021[54]. - Cash inflow from financing activities totaled ¥13,880,000.00, with cash outflow amounting to ¥53,802,683.06, leading to a net cash flow of -¥39,922,683.06[55]. - The ending balance of cash and cash equivalents as of the end of Q1 2021 was ¥146,598,939.52, down from ¥180,187,262.77 at the beginning of the period[55]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,744,408,505.07, down 3.12% from ¥1,800,518,724.44 at the end of the previous year[7]. - The total assets of the company as of January 1, 2021, were adjusted to ¥1,802,128,428.44, reflecting a minor increase due to the new leasing standards[60]. - Total liabilities amounted to CNY 927,906,148.41, with current liabilities totaling CNY 489,898,577.78 and non-current liabilities at CNY 438,007,570.63[62]. - The total equity attributable to shareholders was CNY 687,099,034.95, while total equity reached CNY 872,612,576.03[62]. - The total amount of other payables was CNY 124,380,275.13, reflecting the company's short-term obligations[62]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,169[10]. - The top shareholder, Weng Zanguo, holds 6.92% of the shares, amounting to 15,772,409 shares[10]. - The company did not engage in any repurchase transactions among the top shareholders during the reporting period[11]. Research and Development - Research and development expenses for Q1 2021 were CNY 9,721,554.14, slightly down from CNY 9,910,106.85 in the previous year, indicating a focus on cost management[45]. - The company incurred research and development expenses of CNY 2,992,647.76, down from CNY 4,281,186.85 in the previous year[49]. Risks and Strategies - The company faces significant risks from industry policy changes, drug price reductions, and potential product exits from the National Medical Insurance Directory, which could adversely affect its revenue and profitability[23][24]. - The company is actively working to expand its OTC market and enhance its product structure to mitigate risks associated with price reductions and policy changes in the pharmaceutical industry[22]. Investment and Capital Expenditure - Total funds raised in the current quarter amounted to 13,358.06 million yuan, with a cumulative investment of 2,010.75 million yuan[27]. - The company has committed to invest 14,000 million yuan in various projects, with 9.74% of the total funds utilized so far[28]. - The company plans to temporarily use 50 million yuan of idle raised funds to supplement working capital, with a repayment period not exceeding 12 months[28]. Other Financial Metrics - The company's operating costs for the reporting period were 70.83 million, an increase of 43.44% compared to the same period last year, mainly due to the increase in operating revenue[18]. - The company's other income for the reporting period was 8.08 million, an increase of 422.08% year-on-year, primarily due to an increase in government subsidies received[18]. - The company's investment income for the reporting period was -0.30 million, an increase of 85.45% compared to the same period last year, mainly due to increased long-term equity investment income accounted for using the equity method[18].